> ## Documentation Index
> Fetch the complete documentation index at: https://docs.hi-doctor.ai/llms.txt
> Use this file to discover all available pages before exploring further.

# Orforglipron

> Orforglipron is a once-daily GLP-1 weight-management tablet approved in the US as Foundayo. It has no EU authorisation, so Hi-Doctor cannot prescribe it.

Orforglipron is a weight-management tablet made by Eli Lilly — a pill
version of the same idea behind the GLP-1 injections. It has no marketing
authorisation in the European Union, so a doctor here cannot prescribe it
and you cannot get it from an EU pharmacy, even though it is already
approved in the United States.

<Warning>
  Orforglipron has no EU marketing authorisation for weight management. It
  may be an approved medicine elsewhere — but not something a doctor here can
  prescribe for this.
</Warning>

## What it is

Orforglipron was approved in the United States on 1 April 2026 under the
brand name Foundayo. It acts on the brain's appetite signals so you feel
full sooner and eat less — the same mechanism as the injectable GLP-1
medicines, but as a once-daily tablet.

## How it works

Orforglipron copies the effect of GLP-1, a natural gut hormone that tells
the brain you have eaten enough, so hunger and food intake go down.

## What the studies reported

<Note>
  Every NCT identifier links to its ClinicalTrials.gov record. A readout is
  not the same as peer-reviewed publication.
</Note>

[ATTAIN-1](https://clinicaltrials.gov/study/NCT05869903) compared
orforglipron only against placebo over 72 weeks. There is no head-to-head
trial against the medicines already authorised for weight management in
the EU, and no long-term cardiovascular outcome data have been published.

## What has been reported

| Reported in ATTAIN-1 | 6 mg  | 12 mg | 36 mg | Placebo |
| -------------------- | ----- | ----- | ----- | ------- |
| Nausea               | 28.9% | 35.9% | 33.7% | 10.4%   |
| Constipation         | 21.7% | 29.8% | 25.4% | 9.3%    |

## Can I get it here?

Not for this use. Orforglipron has no EU authorisation, so it cannot be
prescribed or dispensed here for weight management.

## Available medical weight-management options

A licensed doctor decides case by case and never prescribes without
evaluation. These are the options with EU authorisation that a doctor may
consider instead:

<CardGroup cols={2}>
  <Card title="Semaglutide (Wegovy / Ozempic)" icon="circle-info">
    Weekly GLP-1 receptor agonist. A doctor may prescribe it if your BMI and
    history match the indications. Requires follow-up.
  </Card>

  <Card title="Tirzepatide (Mounjaro)" icon="circle-info">
    Dual GLP-1/GIP agonist. Assessed by the doctor based on comorbidities
    and your BMI.
  </Card>

  <Card title="Liraglutide (Saxenda)" icon="circle-info">
    Daily GLP-1 agonist. Indicated in selected patients with elevated BMI
    after medical evaluation.
  </Card>

  <Card title="Orlistat 120mg" icon="circle-info">
    Fat-absorption inhibitor. A non-GLP-1 alternative a doctor may consider
    based on your history. See the
    [Xenical (orlistat) guide](/library/guides/xenical-orlistat).
  </Card>
</CardGroup>

<Card title="Rybelsus (oral semaglutide)" icon="pills">
  A once-daily semaglutide tablet authorised for type 2 diabetes. Any use
  in weight management is an individual medical decision and may be
  off-label.
</Card>

## How Hi-Doctor handles it

Hi-Doctor's doctors review your weight-loss questionnaire and propose an
equivalent weight-management treatment with EU authorisation, rather than
prescribing orforglipron itself. See [how a consultation
works](/essentials/how-it-works), the [treatment areas](/essentials/treatments)
Hi-Doctor covers, and [pricing](/essentials/pricing) for the consultation
fee.

## Sources

* NEJM — ATTAIN-1 (PubMed record)
* Eli Lilly — complete ATTAIN-1 results published in NEJM
* Eli Lilly — FDA approves Foundayo (orforglipron), 1 April 2026
* FDA approval letter — Foundayo (orforglipron), NDA 220934
* ClinicalTrials.gov — [ATTAIN-1 (NCT05869903)](https://clinicaltrials.gov/study/NCT05869903)

## Common questions

<AccordionGroup>
  <Accordion title="What is orforglipron and what is it used for?">
    Orforglipron is a weight-management tablet made by Eli Lilly. It is a pill version of the same idea behind the GLP-1 injections: it acts on the brain's appetite signals so you feel full sooner and eat less. It was approved in the United States on 1 April 2026 as Foundayo.
  </Accordion>

  <Accordion title="Why does Hi-Doctor not prescribe orforglipron?">
    Orforglipron has no EU marketing authorisation for weight management, so a doctor here cannot prescribe it and you cannot get it from an EU pharmacy.
  </Accordion>

  <Accordion title="What did the ATTAIN-1 trial show?">
    ATTAIN-1 compared orforglipron only against placebo over 72 weeks. There is no head-to-head trial against the medicines already authorised for weight management in the EU, and no long-term cardiovascular outcome data have been published. Nausea was reported by 28.9% to 33.7% of participants and constipation by 21.7% to 29.8%, depending on the dose.
  </Accordion>

  <Accordion title="What alternatives can I consider within weight management?">
    Semaglutide, tirzepatide, liraglutide and orlistat are authorised in the EU. A doctor reviews your case and decides which option fits your history and goals.
  </Accordion>

  <Accordion title="What are the main side effects reported in the trial?">
    In ATTAIN-1, nausea was the most common side effect and constipation the second most common. Both were more frequent than with placebo.
  </Accordion>
</AccordionGroup>

## Related reading

* [Obesity](/library/conditions/obesity)
* [Overweight](/library/conditions/overweight)
* [Semaglutide (Wegovy)](/library/medicines/semaglutide)
* [Tirzepatide (Mounjaro)](/library/medicines/tirzepatide)

## Start a consultation

<Card title="Weight-loss consultation" icon="stethoscope" href="https://hi-doctor.ai/consultation/weight-loss/1">
  Answer the weight-loss questionnaire and a registered doctor reviews it.
  They decide whether treatment is appropriate, which one, and at what dose —
  and declining is a normal outcome. See [what it costs](/essentials/pricing)
  and [how the review works](/essentials/how-it-works).
</Card>

<Warning>
  This page is reference information, not medical advice and not a prescription.
  Whether a medicine is appropriate for you is decided by a registered doctor
  after reviewing your consultation.
</Warning>